Belite Bio

Performance

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal degenerative diseases with significant unmet medical needs. The company’s lead candidate, Tinlarebant (LBS-008), is an oral therapy derived from its RBP4 IP portfolio and aims to reduce toxin accumulation in the eye to address geographic atrophy and Stargardt disease. Belite Bio has advanced Tinlarebant through Phase 2 in adolescent STGD1 and is conducting Phase 3 (DRAGON) and Phase 2/3 (DRAGON II) trials in STGD1, as well as Phase 3 (PHOENIX) in GA, with multiple designations including Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, and Fast Track. Headquartered in San Diego, California, the company pursues therapies to treat blinding retinal conditions and related metabolic diseases.